个人简介
教育背景
1982年毕业于北京师范大学化学系。1993-1995年在北京师范大学化学系从事不对称合成研究，并获得硕士学位。1996-1999年在北京师范大学化学系从事天然抗癌药物喜树碱类似物的不对称全合成研究，并获得博士学位。
工作经历
1983－1992年在河北轻化工学院（现改名河北科技大学）从事化学教学和化工产品的开发。2000-2001年在中国医学科学院药物研究所黄量院士课题组做博士后，从事全顺式黄皮酰胺立体异构体的不对称合成研究。
2002-至今一直在中国医学科学院药物研究所工作，从事药物分子设计与合成及新药研发。
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1．Yongqiang Li, Kang Tian, Aifang Qin, Lijian Zhang, Lianchao Huo, Lei Lei, Zhufang Shen, Hongrui Song, Zhiqiang Feng*. Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARgamma. European Journal of Medicinal Chemistry, 76(2014): 182-192.
2．Jianxun Lu, Lei Lei, Yi Huan, Yongqiang Li, Lijing Zhang, Zhufang Shen, Wenxiang Hu, Zhiqiang Feng*. Design, synthesis and activity evaluation of the GK/ PPARγ dual-target-directed ligands as hypoglycemic agents ChemMedChem. 9(2014 ) 922-927.
3．Ke Wang, Yan Li, Li-Jing Zhang, Xiao-Guang Chen,Zhi-Qiang Feng*. Synthesis and in vitro cytotoxic activities of sorafenib derivatives Chinese Chemical Letters. 25(2014), 5, 702-704.
4．Lijian Zhang, KangTian, Yongqiang Li, Lei Lei, Aifang Qin, Lijuan Zhang, HongruiSong, Lianchao Huo, Lijing Zhang, Xiaofeng Jin, Zhufang Shen, Zhi Qiang Feng,*, Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARg, Acta Pharmaceutica Sinica B, 2012, 2(6): 588-597。
5．Hui Peng Song, Kang Tian, Lei Lei, Zhu Fang Shen, Shou Xin Liu, Li Juan Zhang, Hong Rui Song, Xiao Feng Jin, Zhi Qiang Feng,*. Novel N-(pyrimidin-4-yl)thiazol-2-amine derivatives as dual-action hypoglycemic agents that activate GK and PPARg. Acta Pharmaceutica Sinica B. 1(3) (2011): 166-171.
6．Zhiqiang Feng; Chenglie Yin. Stereoselective Synthesis and Characterization of (Z)-(-)-4-(1'-Alkoxyl-1'-alkyloxycarbonyl-methylidene)-5(R)-[(1R)-menthyloxy]-γ-butyrolactones, Synthetic Communications, 41(2011): 507–515.
7．Yong Qiang Li, Yu Liang Zhang, Sheng Quan Hu, Yu Ling Wang, Hong Rui Song, Zhi Qiang Feng*, Lei Lei, Quan Liu, Zhu Fang Shen . Design, synthesis and biological evaluation of novel. glucokinase activators. Chinese Chemical Letters, 22 (2011): 73–76.
8．Zhi-qiang Feng; Ying-Yu Wang; Zong-Ru Guo; Feng-Ming Chu; Piao-Yang Sun. The synthesis of puerarin derivatives and their protective effect on the myocardial ischemia and reperfusion injury, Journal of Asian Natural Products Research，12 (2010): 843.
9．Xia Yuan, Yi Zhang, Haijing Zhang, Jing Jin, Xiangyan Li, He Liu, Zhiqiang Feng, Xiaoguang Chen*，Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr–Abl positive cell lines in vitro and in vivo，Leukemia Research 35 (2011): 237–242.
10. Zhi-qiang Feng; Cheng-Lie Yin. The stable planar conformation of the γ-butyrolactone ring in solution. Chinese Chemical Letters, 21 (2010):187-190
11. Jing Li, Yan Li, Zhiqiang Feng, Xiaoguang Chen. F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. Investigational New Drugs, 28 (2010): 132. IF: 3.072.
12. Zhiqiang Feng, xingzhou Li, guojun Zheng, Liang Hang*. Synthesis and activity in enhancing LTP of clausenamide stereoisomers. Bioorg Med Chem Lett. 19 (2009): 2112-2115.
13. Zhiqiang Feng, fengming chu, zongru guo*, piaoyang sun. Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorganic & Medicinal Chemistry Letters. 19 (2009): 2270–2272.
14. Jing Li, Yan Li, Zhi-qiang Feng, Xiao-guang Chen*. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor F90 against human NSCLC in vitro and in vivo. Cancer Letters, 279 (2009): 213-220.
15. He Liu, Hongyan Li, Zhiqiang Feng, Jun Tai, Yang Meng, Hongbo Wang, Hongqi Xin, Sen Zhang, Mingxin Zuo, Yan Zhang, Xiaoguang Chen*. Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. Leukemia & lymphoma. 50 (2009): 437-446
京公网安备 11010802027423号